Farms.com Home   News

US succeeds in GM corn trade dispute

Jan 03, 2025
By Farms.com

Mexico challenges GM corn import ruling

The US-Mexico-Canada Agreement (USMCA) trade panel has ruled in favor of the United States, stating that Mexico’s ban on genetically modified (GM) corn violates trade regulations due to a lack of adequate scientific risk assessments.

While Mexico has vowed to respect the ruling, it maintains its opposition to GM corn, citing health and biodiversity risks.

The ruling stems from Mexico’s 2023 presidential decree banning GM corn and glyphosate to protect native maize biodiversity and public health. Mexican organizations argue the panel lacks the expertise to assess the health and environmental impacts of GM corn.

"It demonstrates the risks that basic foodstuffs are part of trade agreements and are considered as a commodity and not as a priority good for humanity," emphasised the Sin Maíz No Hay País campaign.

The campaign also highlights the absence of credible evidence from US industry regarding the safety of GM corn, accusing companies of evading rigorous testing. Mexico has proposed a joint risk assessment with the US, but the offer was declined.

Corn holds cultural and agricultural significance in Mexico, home to 64 maize breeds. The government’s defence stressed the need to protect native corn diversity from GM contamination, which has reportedly increased from 1% in 2009 to 33% in 2023, according to a Conahcyt study.

Despite the ruling, Mexico’s stance remains firm, with ongoing efforts to constitutionally ban GM corn planting and consumption. Advocates continue to push for biosafety measures and raise awareness about the risks of transgenic crops.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.